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A method with few markers to determine multicomponents was established and validated
to evaluate the quality of Shenfu injection by ultraperformance liquid chromatography
coupled with a photodiode array detector. The separations were performed on an ACQUITY
UPLC BEH C18 (2.1  50 mm2, 1.7 mm) column. Methanol and 0.1% formic acid aqueous
solution were used as the mobile phase. The flow rate was 0.3 mL/min. 2 aconitum alka-
loids and 12 ginsenosides could be perfectly separated within 15 minutes. Ginsenoside Rg1
and benzoylmesaconine, the easily available active components, were employed as the
maker components to calculate the relative correction factors of other components in
Shenfu injection, Panax ginseng and Aconitum carmichaeli. The external standard method
was also established to validate the feasibility of the method with few markers to deter-
mine multicomponents. Parameter p and the principal component analysis method were
employed to investigate the disparities among batches for the effective quality control of
Shenfu injection. The results demonstrated that the ultraperformance liquid chromatog-
raphy coupled with a photodiode array detector method with few markers to determine
multicomponents could be used as a powerful tool for the quality evaluation of traditional
Chinese medicines and their preparations.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.boratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine,
hang).
s study.
ministration, Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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cines (TCMs) and their preparations have been gaining more
and more attention [1]. The simultaneous determination of
multicomponents was considered to be one of the key
methods to evaluate the quality of TCMs [2,3]. However, the
limited availability of reference standards hampers the wide
popularization for quality control of TCMs. Therefore, it
should be a practical option to use few easily available com-
ponents to simultaneously determine multicomponents for
quality evaluation of TCMs.
Shenfu injection (SFI) was derived from “Shenfu decoc-
tion,” which is an ancient herbal medicinal formula in China
[4]. SFI is composed of extracts of steamed roots of Panax
ginseng and processed lateral roots of Aconitum carmichaeli. SFI
has been used for the treatment of cardiovascular diseases
such as coronary artery disease, myocardial infarct, cardiac
insufficiency, and arrhythmia [5e8]. Aconitum alkaloids and
ginsenosides are main active components of SFI. Aconitum
alkaloids can exhibit cardiotonic, anti-inflammatory, and
analgesic activities [9]. Ginsenosides possess many biological
activities, including anticerebral ischemic injury, neuro-
protective, and cardiotonic activities [10]. Therefore, aconitum
alkaloids and ginsenosides contribute to the curative effects of
SFI.
At present, high-performance liquid chromatography
(HPLC), ultraperformance liquid chromatography coupled
with a photodiode array detector (UPLC-PDA), and liquid
chromatography tandem mass spectrometry are used for
analyzing a few ginsenosides and/or aconitum alkaloids in SFI
[11e13], but the chromatographic analysis time of those
methods are more than 60 minutes. The analysis time is so
long that these methods are not suitable for the effective
quality control of SFI. It was reported that the content of a
single or a few marker compounds might not accurately
reflect the quality of the complex herbal products [14]. In order
to guarantee the clinic safety of SFI, a reasonable method for
simultaneous determination of aconitum alkaloids and gin-
senosides should be established.
UPLC-PDA has become a powerful analytical tool for its fast
separation, sensitive and specific detection, and good chro-
matographic resolution [15,16]. It can shorten analysis time
obviously, compared to the conventional HPLC system with
5 mm particle-packed analytical columns [17e19]. Recently,
HPLCwith a singlemarker to determinemulticomponents has
been used to control the quality of some herbal medicines
[20e22]. Based on the above research, a UPLCmethodwith few
markers to determine multicomponents that belong to
different types of chemicals (UPLC-FMCMC) was proposed to
control the quality of TCMs.
To our knowledge, the UPLC-FMCMC method for quality
control of SFI has not been reported in the literature.
Considering the structural differences of aconitum alkaloids
and ginsenosides, SFI was investigated as a typical example to
validate the new UPLC-FMCMC method for quality control of
TCM preparations. The UPLC-FMCMC method was developed
for the simultaneous quantitative analysis of two aconitum
alkaloids and 12 ginsenosides in SFI. The feasibility andprecision of the UPLC-FMCMCmethod have been discussed in
the present report. UPLC-FMCMC will become an advanta-
geous tool for quality control of TCMs and their preparations.2. Materials and methods
2.1. Materials, chemicals, and reagents
Twenty-two batches of SFIs (number of batches: 120609,
110804, 131006010, 131005010, 131013010, 131008010,
130902010, 130813010, 130812010, 130904010, 130905010,
130903010, 130505010, 130506010, 130508010, 130606010,
130605010, 130604010, 130713010, 130715010, 130705010, and
130703010) were obtained from YaAn Sanjiu Pharmaceutical
Co., Ltd. (Sichuan, China) and deposited at the Academy of
Traditional Chinese Medicine in Tianjin. Five samples of P.
ginseng (P1eP5) and six samples of A. carmichaeli (S1eS6),
gathered from different pharmacies of Tianjin, China were
authenticated by Dr Yan-Xu Chang, Tianjin University of
Traditional ChineseMedicine, Tianjin, China. Acetonitrile and
methanol (Tianjin Concord Science Co. Ltd., Tianjin, China)
were of HPLC grade. HPLC-grade formic acid was purchased
from Tedia Company Inc (Fairfield, OH, United States of
American). Deionized water was purified with a Milli-Q Aca-
demic ultrapure water system (Millipore; Milford, MA, USA).
Reference standards such as ginsenoside Re (Re), ginsenoside
Rg1 (Rg1), ginsenoside Rf (Rf), ginsenoside Rb1 (Rb1), ginseno-
side Rc (Rc), ginsenoside Rb2 (Rb2), ginsenoside Rb3 (Rb3), gin-
senoside Rd (Rd), ginsenoside S-Rg2 (S-Rg2), ginsenoside S-Rh1
(S-Rh1), ginsenoside S-Rg3 (S-Rg3), and ginsenoside S-Rh2 (S-
Rh2) (purity > 98%) were purchased from Chengdu Must Bio-
technology Co., Ltd (Chengdu, China). Benzoylhypacoitine
and benzoylmesaconine (purity > 98%) were purchased from
the National Institute for the Chinese National Institute of
Control of Pharmaceutical and Biological Products (Beijing,
China). Other reagents were of analytical grade.
2.2. Preparation of sample solutions
The SFI solutions were diluted with methanol. After centri-
fugation for 10 minutes at 1098g, the supernatant was
transferred into another centrifuge tube. The final solution
was filtered through a membrane (0.22 mm) until analysis.
Then, 4 mL aliquot of the solution was injected into the UPLC
system for analysis.
Dried and powdered P. ginseng (0.300 g) and A. carmichaeli
(0.400 g) were ultrasonically extracted with 10 mL methanol
for 30 minutes and cooled at room temperature. It was made
up to the volume with methanol and subsequently centri-
fuged for 10minutes at 1098g. An aliquot of 4 mL supernatant
solution was used for UPLC analysis.
2.3. Preparation of standard solutions
The standard stock solutions of ginsenosides Re (1.03 mg/mL),
Rg1 (1.02 mg/mL), Rf (1.00 mg/mL), Rb1 (1.03 mg/mL), Rc
(1.01 mg/mL), Rb2 (1.02 mg/mL), Rb3 (0.98mg/mL), Rd (1.01 mg/
mL), S-Rg2 (1.03 mg/mL), S-Rh1 (1.01 mg/mL), S-Rg3 (1.02 mg/
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mL); and benzoylmesaconine (1.03 mg/mL) were prepared in
methanol. Appropriate volumes of each stock solution were
calculated andmixed together. Then, the mixture was diluted
serially to achieve the standard working solutions. All solu-
tions were kept at 4C until use.
2.4. UPLC analysis
All analyses were performed using a Waters Acquity UPLC
System (Waters Corp., Milford,MA, USA) consisting of a binary
solvent manager, a sampler manager, a column compart-
ment, and a PDA (Waters Acquity model code UPD), all
controlled by the Waters Empower 2 data station software
(Waters Corp.).
The separations were achieved on an ACQUITY UPLC BEH
C18 (1.7 mm, 2.1 mm  50 mm) column. Formic acid aqueous
solution (0.1%, v/v) and methanol (B) were used as mobile
phases. The gradient elution was conducted as follows:
30e52% (v/v) B at 0e4 minutes; 52e57% B at 4e6 minutes;
57e65% B at 6e7 minutes; 65e69% B at 7e8 minutes; 69e73%
B at 8e9 minutes; 73e75% B at 9e10 minutes; 75e80% B at
10e11 minutes; 80e90% B at 11e13 minutes; and 90e30% B at
13e15 minutes. The flow rate was set at 0.3 mL/min. The
column and sample temperatures were maintained at 50C
and 15C, respectively. The total run time for analysis was 15
minutes. The injection volume was 4 mL. DetectionFig. 1 e Representative chromatograms for simultaneous quanti
Mixed standards at 203 nm; (B) mixed standards at 235 nm; (C) S
sample at 235 nm. Peak 1 represents Re, peak 2 Rg1, peak 3 Rf, p
peak 9 Rb3, peak 10 Rd, peak 11 S-Rg3, peak 12 S-Rh2, peak 13 bwavelengths were set at 235 nm for alkaloids and 203 nm for
ginsenosides.
2.5. Statistical analysis
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was used for the
data analysis.3. Results and discussion
3.1. Optimization of chromatographic conditions
The chromatographic conditions were optimized in the study
in order to obtain better resolution of adjacent peaks. The
different mobile phases (acetonitrileewater and methanole-
water), column temperatures (30C, 40C, and 50C), flow rates
(0.2mL/min, 0.3mL/min, and 0.4mL/min), and concentrations
of additive (0.1%, 0.2%, and 0.3% formic acid)were optimized in
our studies. The results showed that good resolution and a
symmetric peak shapewere obtainedwhenmethanoleformic
acid aqueous solution (0.1%)was selected as amobile phase, at
a temperature of 50C and a flow rate of 0.3 mL/min under
gradient elutionmodes.On the basis of the absorptionmaxima
of the 14 compounds, dual wavelengths of 203 nm and 235 nm
were set to monitor signals of ginsenosides and alkaloids,
respectively. The typical chromatogram is illustrated in Fig. 1.fication of the 14 active compounds in Shenfu injection: (A)
henfu injection sample at 203 nm; and (D) Shenfu injection
eak 4 S-Rg2, peak 5 S-Rh1, peak 6 Rb1, peak 7 Rc, peak 8 Rb2,
enzoylmesaconine, and peak 14 benzoylhypacoitine.
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Due to the lack of many highly purified chemical references,
sometimes it is difficult to obtain multiple components for
quantitative analysis of TCM. It may be an alternative
approach to select a few chemicals as references for deter-
mining other ingredients with similar chemical structures.
This approach is very feasible without sufficient reference
substances. Among the components in SFI, benzoylmesaco-
nine and ginsenoside Rg1 were chosen as markers for other
aconitum alkaloids and ginsenosides in this study, respec-
tively. The relative correction factors for other components
were calculated by two different methods in the study. The
intercepts of the regression equations of the markers and
other components were calibrated to zero (y ¼ ax þ b to be
y ¼ ax). The relative correction factors were calculated by the
ratios of the coefficients (RCF ¼ a1/a2) [23]. The other way was
in accordance with the rationale of quantitative analysis of
multicomponents by a single marker, that is the relative
correction factors:

fm

x
 ¼ ðAm=CmÞ Ax=CxÞ;=
where fm/x is the relative correction factor,Am andAx are peak
areas, and Cm and Cx are the concentrations of themarker and
other components, respectively [24]. In our study, the relative
correction factors of aconitum alkaloids and ginsenosides,
except for benzoylmesaconine and ginsenoside Rg1, were
optimized according to these methods. The results showedTable 1 e Calibration curves, LOD, and LOQ of the investigated
Analytes RCFs Linear re
Regressive equation
Re 1.20 y¼1743.4x+1131.2
y¼3351.2x+996.54
Rg1 1.00 y¼4009.8x+1131.2
Rf 0.90 y¼4465.5x+1131.2
y¼4488.9x1757.4
S-Rg2 0.86 y¼4678.5x+1131.2
y¼4735.2x3296.3
S-Rh1 0.60 y¼6717.1x+1131.2
y¼6782.1x3648.3
Rb1 0.40 y¼9943.7x+1131.2
y¼10119x10622
Rc 1.35 y¼2966.1x+1131.2
y¼3007x3809.8
Rb2 1.50 y¼2673.8x+1131.2
y¼2697.2x2038.9
Rb3 2.30 y¼1743.4x+1131.2
y¼2064.02x1340.7
Rd 0.90 y¼4446.1x+1131.2
y¼4381.2x+4999
S-Rg3 0.82 y¼4894.5x+1131.2
y¼4969.3x5026.9
S-Rh2 10.5 y¼383.66x+1131.2
y¼621.16x628.36
Benzoylmesaconine 1.00 y¼7478.9x+100.21
Benzoylhypacoitine 8.80 y¼849.88x+100.21
y¼1065.1x159.6
In the regression equation, the x value is the concentration of analytes (m
LOD ¼ limit of detection; LOQ ¼ limit of quantification; RCF ¼ relative cothat ginsenoside Rb3 and benzoylhypacoitine showed good
results with the second method, while the other standards
were more favored by the first one. The relative correction
factors of the 14 components were 1.20, 1.00, 0.90, 0.86, 0.60,
0.40, 1.35, 1.50, 2.30, 0.90, 0.82, 10.45, 1.00, and 8.80. Based on
the relative correction factors, the other 12 components could
be determined using the UPLC-PDA method.
3.3. Method validation of UPLC-FMCMC
The method was validated in terms of limit of quantification
(LOQ), limit of detection (LOD), linearity, precision, stability,
repeatability, and recovery.
3.4. Linearity, linear range, LODs, and LOQs
Stock solutions were diluted to appropriate concentrations in
order to construct calibration curves. All calibration curves
were calculated based on linear regression analysis of the
plots of peak areas (y) versus concentrations (x, mg/mL) for the
14 reference compounds. The relative correction factors, cor-
relation coefficients (R2), linear ranges, and regression equa-
tions are listed in Table 1. As a consequence, each coefficient
of regression (R2) was > 0.9991, as determined by the least
square analysis, which suggests good linearity between peak
areas (y) and compound concentrations (x) over a wide con-
centration range. The lowest concentration of working solu-
tion was diluted with methanol to a series of appropriatecompounds.
gression data LOD
(mg/mL)
LOQ
(mg/mL)Test range (mg/mL) R2
5.06~636 0.9997 0.270 0.940
2.20~275 0.9995 0.210 0.650
2.20~275 0.9997 0.200 0.630
1.98~372 0.9997 0.300 0.820
1.20~150 0.9991 0.120 0.350
1.89~111 0.9997 0.170 0.250
0.76~95 0.9998 0.007 0.025
1.31~236 0.9997 0.080 0.380
0.760~95.0 0.9997 0.004 0.013
0.89~111 0.9997 0.080 0.250
0.76~95.0 0.9997 0.008 0.025
2.97~372 0.9997 0.270 0.850
1.20~150 0.9996 0.125 0.320
3.30~412 0.9997 0.300 0.940
1.20~150 0.9991 0.115 0.300
2.87~359 0.9997 0.260 0.820
0.76~95.0 0.9992 0.003 0.008
1.98~248 0.9997 0.180 0.570
0.760~95.0 0.9993 0.008 0.025
1.80~225 0.9997 0.160 0.520
0.760~95.0 0.9993 0.010 0.040
22.9~287 0.9997 2.09 6.580
0.760~95.0 0.9993 0.010 0.032
0.760~95.0 1.0000 0.030 0.080
2.50~308 0.9997 0.180 0.480
0.280~35.0 0.9995 0.010 0.032
g/mL), the y value is the peak area.
rrection factor.
Table 2 e Precision, repeatability, stability of the
investigated compounds (n ¼ 6).
Analytes Precision
(RSD)
Repeatability
(RSD)
Stability
(RSD)
Re 3.11 1.64 3.44
Rg1 1.32 2.03 3.92
Rf 3.47 3.65 0.87
S-Rg2 1.10 2.60 2.27
S-Rh1 1.36 2.27 1.72
Rb1 2.77 1.62 1.09
Rc 1.68 2.20 3.51
Rb2 3.12 3.64 3.46
Rb3 0.91 2.13 1.10
Rd 1.92 3.32 4.54
S-Rg3 2.27 3.51 3.83
S-Rh2 1.75 4.50 1.73
Benzoylmesaconine 1.06 1.11 1.55
Benzoylhypacoitine 4.73 4.20 3.80
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ysis. The LOD and LOQ for each compound under the optimal
chromatographic conditions were determined at signal-to-
noise ratios of 3 and 10, respectively. The LODs and LOQs of
the 14 compounds are shown in Table 1. The LODs and LOQs
were 0.003e0.210 mg/mL and 0.013e0.650 mg/mL, respectively,
which indicated high sensitivity under these UPLC conditions.
3.5. Precision, repeatability, and stability
The precision was investigated by one sample solution using
six replicates. As shown in Table 2, all relative standard de-
viations (RSDs) of the precision of the method were < 5% indi-
cating that the method was precise enough for quantitative
evaluation of the analytes in SFI. The repeatability of the
methodwasassessedbyperforming replicate analysis (n¼ 6) of
the sample solutions. RSDs of repeatability were < 5%, which
demonstrates that the analytical method was reproducible for
the components analyzed. Stability of those analytes was
assessed by analyzing SFI under the following conditions:
0hour, 2hours, 4hours, 6hours, 8hours, 12hours,and24hours.
The results indicated that the RSDs of the analytes were < 5%,
indicating that the sample solutions were stable for 24 hours.Table 3 e Recoveries of the investigated compounds by UPLC-
Analytes Original
(mg/mL)
Spiked
(mg/mL)
Re 16.6 15.0
Rg1 25.0
Rf 8.14 10.0
S-Rg2 7.42 10.0
S-Rh1 3.76 5.00
Rb1 8.56 10.0
Rc 14.8 15.0
Rb2 10.2 10.0
Rb3 2.23 2.50
Rd 3.16 4.00
S-Rg3 3.65 4.00
S-Rh2 4.39 4.00
Benzoylmesaconine 5.00
Benzoylhypacoitine 0.47 1.003.6. Recovery
The recovery experiment was performed by adding a known
amount of reference compound to a certain amount of SFI.
The quantity of each analyte was subsequently realized from
the corresponding calibration curve and the relative correc-
tion factors. The recovery of each compound was calculated
using the following formula:
recovery (%) ¼ (amount found e original amount)/amount
added  100%.
As shown in Table 3, the average recoveries of the inves-
tigated targets ranged from 91.4% to 105%, and all RSD values
were < 5%. In order to validate the accuracy of the developed
UPLC-FMCMC method, the recoveries were evaluated by the
traditional methods (external standard method). The results
showed that the recovery of each component ranged from
95.4% to 105% (Table 4). These results were consistent with
those obtained by the developed UPLC-FMCMC method,
which demonstrated that this method was reliable and ac-
curate for the measurement of two aconitum alkaloids and 12
ginsenosides in SFI.
3.7. Application of UPLC-FMCMC
The newly developed UPLC-FMCMC method was used to
simultaneously determine the two types of components in
SFI. Twenty-two batches of SFIs obtained from the same
manufacturer were tested. The contents of 14 investigated
components are listed in Table 5. The results indicated that
among the 14 compounds analyzed, ginsenoside Rg1 was
present in the highest concentrations (ranging from 71.8 mg/
mL to 105 mg/mL), followed by Rc (52.0e92.0 mg/mL), Re
(47.2e66.4 mg/mL), and Rb2 (41.0e59.0 mg/mL). All the concen-
trations of the four components were > 40.0 mg/mL. The
maximum concentrations of Rb1 (28.2e49.6 mg/mL), S-Rg2
(20.6e29.6 mg/mL), Rf (8.48e32.6 mg/mL), S-Rg3 (11.7e27.1 mg/
mL), benzoylmesaconine (5.52e26.2 mg/mL), S-Rh1
(8.32e15.6 mg/mL), Rb3 (7.44e11.8 mg/mL), Rd (5.50e17.1 mg/mL),
and S-Rh2 (14.4e18.2 mg/mL) were in the range of 5.00e40.0 mg/FMCMC.
Found
(mg/mL)
Recovery (%) RSD (%)
32.6 105 0.50
17.9 98.1 1.05
17.4 99.3 0.78
8.37 92.3 0.86
17.7 91.4 0.23
29.7 99.6 0.41
20.2 99.8 0.84
4.58 94.0 1.00
7.40 106 4.02
7.55 97.6 1.55
8.51 103 1.04
1.43 96.0 3.78
Table 4 e Recoveries of the investigated compounds by traditional UPLC method.
Analytes Original
(mg/mL)
Spiked
(mg/mL)
Found
(mg/mL)
Recovery (%) RSD (%)
Re 16.6 15.0 32.1 103 1.06
Rg1 25.4 25.0 50.9 102 1.82
Rf 8.42 10.0 18.3 99.2 0.83
S-Rg2 7.80 10.0 17.9 101 1.55
S-Rh1 4.07 5.00 8.96 97.8 2.08
Rb1 8.99 10.0 18.5 95.4 0.46
Rc 15.4 15.0 31.0 104 1.93
Rb2 10.7 10.0 21.1 104 1.35
Rb3 2.17 2.50 4.57 96.0 2.49
Rd 3.26 4.00 7.41 104 3.61
S-Rg3 3.74 4.00 7.83 102 2.67
S-Rh2 4.13 4.00 8.01 96.9 1.11
Benzoylmesaconine 4.68 5.00 9.61 98.5 2.73
Benzoylhypacoitine 0.74 1.00 1.79 105 2.89
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trations (ranging from 1.74 mg/mL to 4.14 mg/mL). In order to
investigate the difference between the newly developedUPLC-
FMCMC method and the traditional methods, simultaneous
determination of the 14 investigated components present in
these samples was also carried out at the same time by the
traditional method. As shown in Table 5, no remarkable dif-
ferences (RDs < 5%) were observed between the two methods
(the traditional method and the UPLC-FMCMC method).
In order to further verify the developed UPLC-FMCMC
method, the two crude herb components of SFI, roots of P.
ginseng and processed lateral roots of A. carmichaeli, were
analyzed under the UPLC system. The chromatograms were
comparedwith the chromatograms of SFI, which are shown in
Fig. 2. The results demonstrated that the main components in
SFI were from P. ginseng, and the chromatograms of SFI and P.
ginseng at 203 nm were nearly the same. Contents of the 14
investigated components in P. ginseng and A. carmichaeli are
listed in Tables 6 and 7. The results indicated that among the
14 analyzed compounds, contents of ginsenoside Rg1 were
highest (ranging from 0.85 mg/g to 1.11 mg/g), followed by
those of Rc (0.52e1.12 mg/g), Re (0.55e0.74 mg/g), and Rb2
(0.43e1.02 mg/g). The contents of Rf (0.27e0.54 mg/g), Rb1
(0.29e0.41 mg/g), S-Rh2 (0.23e0.31 mg/g), S-Rg3 (0.11e0.22 mg/
g), Rd (0.09e0.30 mg/g), S-Rg2 (0.03e0.23 mg/g), Rb3
(0.09e0.12mg/g), and S-Rh1 (0.03e0.08mg/g) were in the range
of 0.03e0.54 mg/g in P. ginseng extract. The content of ben-
zoylmesaconine was in the range of 0.68e0.90 mg/g and that
of benzoylhypacoitine 0.21e0.31mg/g in A. carmichaeli extract.
As shown in Tables 6 and 7, no remarkable differences
(RDs < 5%) were observed between the two methods (the
traditional method and the UPLC-FMCMC method). As a
consequence, the developed UPLC-FMCMC method could be
applied for simultaneous determination of active components
for the quality evaluation of SFI, P. ginseng, and A. carmichaeli.3.8. Parameter p analysis
To investigate the quality fluctuations among batches, a
parameter p was employed. In general, a value in the range of
75e125% was considered acceptable [25]. The value of
parameter p was calculated using the following formula:p ¼ Ch=Ci  100%
(Ch represents the measured concentration of the compo-
nents in each batch and Ci denotes the average concentration
of the components in the 22 batches). As illustrated in Fig. 3,
only the p values of Re, Rg1, and Rb3 were in the range of
75e125%, while for others the values were all beyond this
range, with the highest p values exceeding 175% (recorded for
S-Rg3 and benzoylhypacoitine), indicating that great fluctua-
tions may exist among batches. Moreover, the results
demonstrated that both S-Rg3 and benzoylhypacoitine were
mainly responsible for the fluctuation among batches.
3.9. Principal component analysis
To investigate further disparities among batches, principal
component analysis was employed. The sum of PC1 and PC2
were above 75.6% of the total variance, which meant that the
two PCs were sufficient to describe the variability. The score
plot and the loading plot for active components generated
from a comparison of the two principal components are
depicted in Fig. 4. As shown in Fig. 4A, 22 batches were clas-
sified into two groups, which showed the disparities between
different batches. A clear classification of two clusters, based
on the production date, could be observed: PC2 values of
samples made in 2013 were comparatively clustered into one
group, while those made in 2011 and 2012 were clustered into
other groups. The loading plot highlights the importance of
the contribution of each variable to the sample classification
in the principal component analysis. As can be seen in the
loading plot in Fig. 4B, the component regions that most
strongly contributed to the separation of the samples corre-
sponded to benzoylhypacoitine, S-Rg2, S-Rg3, S-Rh1, and Rb1,
based on PC2 values, which indicates that the fluctuation of
components had a strong influence on the disparity among
batches. From Table 5, the average contents of benzoylhypa-
coitine, S-Rg2, S-Rg3, S-Rh1, and Rb1 in the 20 batches of
samples made in 2013 were 2.42 ± 0.63 mg/mL, 22.99 ± 2.06 mg/
mL, 18.52 ± 3.79 mg/mL, 11.66 ± 1.37 mg/mL, and 38.93 ± 5.08 mg/
mL, respectively. Among these marker components of the
samplesmade in 2011 and 2012, the contents of S-Rg2 (31.2 mg/
mL and 28.6 mg/mL, respectively) and S-Rh1 (16.3 mg/mL and
Table 5 e Contents of 12 ginsenosides and two aconitum alkaloides in 22 batches of Shenfu injection (mg/mL).
No. Batch Method Re Rg1 Rf S-Rg2 S-Rh1 Rb1 Rc Rb2 Rb3 Rd S-Rg3 S-Rh2 Benzoylmesaconine Benzoylhypacoitine
1 120609 E.M 66.6 102 33.6 31.2 16.3 36.0 61.6 43.0 8.68 13.0 14.9 16.5 18.7 2.72
N.M 66.4 32.6 29.6 15.6 34.2 59.2 41.0 8.94 12.7 14.6 16.8 2.78
R.D 0.13 3.32 4.86 4.08 4.81 4.03 4.65 2.97 3.03 2.30 1.55 2.77
2 110804 E.M 60.0 105 36.6 28.6 15.9 47.6 67.6 53.6 8.60 17.6 22.2 14.5 26.2 2.24
N.M 59.8 35.4 27.8 15.4 46.2 65.2 51.6 8.82 17.1 22.0 14.4 2.18
R.D 0.14 3.02 2.60 2.95 3.19 3.56 3.55 2.61 2.93 0.80 1.20 2.06
3 131006010 E.M 56.8 90.2 11.4 21.2 11.5 38.0 64.8 46.2 8.88 7.82 17.7 15.7 17.6 3.14
N.M 57.0 11.1 20.0 11.0 36.0 62.6 44.2 8.68 8.02 17.6 16.4 3.34
R.D 0.150 1.86 5.53 3.99 5.22 3.89 4.24 2.29 2.63 0.54 4.11 5.90
4 131005010 E.M 58.2 88.0 11.9 22.2 10.7 34.4 66.2 44.8 7.96 7.80 15.9 15.8 16.5 2.38
N.M 58.2 11.3 21.2 10.5 32.2 63.8 42.8 7.80 8.00 16.3 16.5 2.38
R.D 0.15 5.08 4.29 2.01 5.89 3.79 4.41 2.14 2.65 2.31 4.51 0.29
5 131013010 E.M 61.8 87.0 12.5 20.2 11.3 41.6 75.0 50.2 9.44 6.56 20.2 18.1 17.6 2.84
N.M 61.8 12.1 19.3 11.1 39.8 72.6 48.4 9.54 6.78 20.1 18.2 2.94
R.D 0.16 3.22 3.90 1.81 4.68 3.19 3.82 1.07 3.46 0.25 0.56 3.74
6 131008010 E.M 55.4 84.8 11.5 22.0 13.2 37.6 72.4 45.4 10.2 7.26 17.1 16.9 21.2 2.62
N.M 55.4 11.3 21.8 12.6 35.6 70.0 43.6 9.82 7.08 17.5 16.7 2.66
R.D 0.14 1.82 0.70 4.78 5.29 3.35 4.32 3.56 2.50 2.35 1.39 1.90
7 130902010 E.M 51.6 75.4 10.4 21.2 10.9 30.2 54.6 37.2 7.50 5.62 14.3 16.2 15.7 1.74
N.M 51.6 10.0 21.6 10.3 28.2 52.0 35.2 7.44 5.56 14.0 16.0 1.74
R.D 0.13 3.48 2.04 5.38 6.79 4.85 5.47 0.75 0.95 2.04 0.70 0.60
8 130813010 E.M 47.4 72.2 10.5 21.6 10.0 33.6 63.2 42.6 7.70 5.90 13.9 15.9 14.6 1.80
N.M 47.4 9.90 20.8 9.74 31.6 60.8 40.6 7.28 6.02 14.0 16.7 1.78
R.D 0.12 5.37 3.52 2.82 6.02 4.02 4.67 5.45 1.99 0.85 4.84 0.80
9 130812010 E.M 47.0 71.8 10.8 21.2 8.54 32.8 62.8 41.6 8.28 6.40 11.4 16.2 14.4 1.84
N.M 47.2 10.6 21.8 8.32 30.8 60.2 39.8 8.36 6.24 11.7 16.0 1.78
R.D 0.12 1.51 2.03 2.53 6.20 4.06 4.79 1.03 2.49 2.38 0.71 3.44
10 130904010 E.M 47.8 74.4 8.80 20.4 10.1 31.6 59.0 39.0 8.68 5.90 14.2 17.2 15.0 1.90
N.M 47.8 8.48 20.6 10.0 29.6 56.4 41.0 8.46 5.98 14.1 16.7 1.78
R.D 0.12 3.60 2.06 0.62 6.48 4.40 5.10 2.61 1.19 1.14 2.61 5.83
11 130905010 E.M 49.4 79.6 11.8 25.2 12.0 35.0 67.2 42.8 9.40 5.68 19.8 16.5 15.6 1.78
N.M 49.6 11.2 24.6 11.7 33.0 64.8 40.8 8.90 5.96 19.3 17.4 1.74
R.D 0.13 5.13 2.02 2.52 5.76 3.71 4.65 5.37 4.92 2.15 5.48 1.30
12 130903010 E.M 63.0 103 12.3 22.8 11.5 37.3 73.3 45.8 10.6 7.70 18.1 15.7 16.7 3.46
N.M 63.2 11.9 22.2 11.3 35.3 70.8 43.8 10.7 7.80 18.0 16.3 3.52
R.D 0.16 3.28 2.40 2.25 5.35 3.3 4.29 1.02 1.41 0.28 3.88 1.89
13 130505010 E.M 62.6 97.8 12.4 25.6 10.7 40.2 76.6 49.8 12.4 6.52 16.2 17.2 11.56 2.30
N.M 62.8 12.0 25.0 10.9 38.2 74.2 47.8 11.9 6.72 16.0 16.8 2.26
R.D 0.16 3.26 1.96 1.70 4.89 3.11 3.86 4.45 2.95 1.16 2.50 1.36
14 130506010 E.M 63.0 104. 17.1 27.4 14.4 51.4 94.2 61.0 12.4 8.42 26.9 16.8 11.78 2.74
N.M 63.2 16.7 25.8 14.0 49.6 92.0 59.0 11.8 8.64 27.1 16.7 2.82
R.D 0.16 2.43 5.37 2.52 3.61 2.29 3.00 4.56 2.62 0.59 0.67 3.00
(continued on next page)
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Table 5 e (continued )
No. Batch Method Re Rg1 Rf S-Rg2 S-Rh1 Rb1 Rc Rb2 Rb3 Rd S-Rg3 S-Rh2 Benzoylmesaconine Benzoylhypacoitine
15 130508010 E.M 59.0 97.6 13.4 25.8 11.0 41.2 75.8 49.2 10.1 7.58 21.0 16.8 6.04 2.60
N.M 59.2 12.8 25.2 10.8 39.4 73.4 47.2 9.94 7.78 21.4 17.0 2.64
R.D 0.15 4.44 1.94 2.12 4.74 3.15 3.93 1.75 2.73 2.01 1.67 1.82
16 130606010 E.M 58.8 102 13.4 24.4 13.5 43.4 80.0 53.0 10.0 6.80 21.8 15.2 5.52 1.92
N.M 59.0 12.8 24.0 13.3 41.4 77.6 51.0 9.84 7.08 21.4 15.6 1.80
R.D 0.15 4.44 1.31 1.69 4.47 2.92 3.58 1.91 4.21 1.69 2.17 6.56
17 130605010 E.M 59.2 103 10.8 23.8 12.6 43 80.0 52.2 9.12 6.66 19.9 16.3 5.64 2.22
N.M 59.4 10.6 22.8 12.0 41.2 77.6 50.2 8.76 6.68 19.6 17.2 2.18
R.D 0.15 2.07 3.91 5.10 4.49 2.92 3.65 3.95 0.17 1.52 6.01 2.22
18 130604010 E.M 62.2 101 12.4 25.4 11.4 43.2 71.0 53.0 11.4 6.76 16.8 17.3 6.94 1.86
N.M 62.2 12.0 24.4 11.0 41.2 68.6 51.0 11.0 6.80 16.9 18.1 1.78
R.D 0.16 3.21 3.56 4.04 4.48 3.45 3.58 3.04 0.50 0.36 4.64 4.21
19 130713010 E.M 57.4 95.6 12.5 21.8 13.2 42.6 80.8 57.2 9.46 7.52 25.3 16.5 14.9 3.96
N.M 57.6 12.1 21.2 12.6 40.8 78.4 55.4 9.36 7.74 25.1 17.2 4.14
R.D 0.15 3.33 2.57 4.79 4.50 2.88 3.24 1.03 2.92 0.60 4.41 4.79
20 130715010 E.M 63.0 109 14.7 23.4 12.6 38.6 74.2 48.4 11.0 5.22 19.9 17.2 20.2 3.10
N.M 63.2 14.3 23.8 11.92 36.6 71.8 46.4 10.8 5.50 20.0 17.7 3.26
R.D 0.16 2.65 1.99 5.12 5.12 3.24 4.01 1.99 5.28 0.57 3.23 5.57
21 130705010 E.M 55.2 95.4 12.4 23.2 11.9 40.2 78.4 51.8 9.96 7.40 20.6 15.6 15.9 1.88
N.M 55.4 12.2 23.6 11.2 38.2 76.0 50.0 9.96 7.54 20.5 16.2 1.94
R.D 0.14 1.63 1.99 5.51 4.88 3.00 3.67 0.05 1.98 0.64 3.71 3.37
22 130703010 E.M 60.6 100 13.0 21.0 12.1 42.6 82 53.2 10.2 6.54 19.4 16.2 9.46 2.36
N.M 60.8 12.6 21.4 11.8 40.6 79.6 51.4 9.98 6.84 19.3 17.1 2.34
R.D 0.16 2.61 2.04 2.08 4.56 2.82 3.55 1.66 4.48 0.48 5.72 0.68
E.M ¼ concentration calculated by traditional method; N.M ¼ concentration calculated by new developed method; R.D ¼ relative deviation.
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Fig. 2 e Representative chromatograms for simultaneous quantification of the 14 active compounds: (A) Shenfu injection at
203 nm; (B) Panax ginseng extract; (C) Shenfu injection at 235 nm; and (D) Aconitum carmichaeli extract. Peak 1 represents Re,
peak 2 Rg1, peak 3 Rf, peak 4 S-Rg2, peak 5 S-Rh1, peak 6 Rb1, peak 7 Rc, peak 8 Rb2, peak 9 Rb3, peak 10 Rd, peak 11 S-Rg3,
peak 12 S-Rh2, peak 13 benzoylmesaconine, and peak 14 benzoylhypacoitine.
Table 6 e Contents of 12 ginsenosides in Panax ginseng (mg/g).
No. Method Re Rg1 Rf S-Rg2 S-Rh1 Rb1 Rc Rb2 Rb3 Rd S-Rg3 S-Rh2
P1 E.M 0.56 0.87 0.35 0.03 0.08 0.29 0.98 1.02 0.12 0.14 0.17 0.24
N.M 0.55 0.34 0.03 0.09 0.28 0.95 1.00 0.12 0.14 0.17 0.23
R.D 1.66 3.84 3.57 4.04 2.28 3.00 2.02 2.39 0.42 0.73 2.53
P2 E.M 0.63 1.06 0.45 0.08 0.03 0.35 0.52 0.44 0.12 0.09 0.22 0.31
N.M 0.62 0.43 0.07 0.03 0.33 0.50 0.44 0.11 0.09 0.22 0.32
R.D 1.46 2.88 3.35 1.93 4.60 3.80 1.28 4.43 0.18 0.95 2.91
P3 E.M 0.63 1.11 0.54 0.09 0.03 0.36 0.55 0.64 0.15 0.12 0.11 0.29
N.M 0.62 0.52 0.08 0.03 0.34 0.54 0.62 0.16 0.11 0.11 0.29
R.D 1.46 2.27 2.74 1.91 4.44 2.66 3.74 3.66 2.00 0.30 1.97
P4 E.M 0.68 0.88 0.28 0.23 0.06 0.41 0.70 0.75 0.05 0.11 0.17 0.23
N.M 0.67 0.27 0.23 0.06 0.41 0.67 0.72 0.05 0.11 0.17 0.24
R.D 1.32 1.50 0.06 5.00 1.32 4.70 3.08 1.10 0.41 0.73 4.11
P5 E.M 0.74 0.85 0.27 0.07 0.04 0.38 1.12 0.43 0.10 0.30 0.13 0.30
N.M 0.75 0.27 0.07 0.04 0.37 1.09 0.41 0.10 0.31 0.13 0.31
R.D 0.56 1.51 3.93 1.80 1.53 2.47 3.71 4.61 2.21 0.45 3.40
E.M ¼ concentration calculated by traditional method; N.M ¼ concentration calculated by new developed method; R.D ¼ relative deviation.
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Table 7 e Contents of two aconitum alkaloides in Aconitum carmichaeli (mg/g).
No. Method Benzoylmesaconine Benzoylhypacoitine
S1 E.M 0.90 0.30
N.M 0.31
R.D 3.68
S2 E.M 0.68 0.21
N.M 0.22
R.D 2.78
S3 E.M 0.97 0.28
N.M 0.27
R.D 0.84
S4 E.M 0.78 0.25
N.M 0.24
R.D 2.14
S5 E.M 0.75 0.21
N.M 0.22
R.D 2.35
S6 E.M 0.75 0.31
N.M 0.33
R.D 3.77
E.M ¼ concentration calculated by traditional method; N.M ¼ concentration calculated by new developed method; R.D ¼ relative deviation.
Fig. 3 e Box chart of 14 components from 22 batches of Shenfu injection.
Fig. 4 e PCA analysis of 22 batches of Shenfu injection samples: (A) score plot and (B) loading plot. PCA ¼ principal
component analysis; REGR (Regression). The number “1 to 22” represent different batches of Shenfu injection. 1 was
produced in 2012, 2 was 2011 and 3 to 22 was made in 2013.
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j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 2 6 7e2 7 8 27715.9 mg/mL, respectively) were higher than the average con-
tents of samples made in 2013. This may be the reason why
PC2 values of batches made in 2011 and 2012 were clustered
into other groups. Therefore, more attention should be paid to
study and normalize the contents of benzoylhypacoitine, S-
Rg2, S-Rg3, S-Rh1, and Rb1 for ensuring the quality of SFI. These
components have been selected as makers in the method
developed for the quality control of SFI.4. Conclusion
A simple and rapid UPLC-PDA method with few markers to
determinemulticomponents were developed and validated to
simultaneously determine two aconitum alkaloids and 12
ginsenosides in SFI. Method validation revealed that the
method was acceptable as a practical technique and fulfilled
the routine quality control requirements of SFI. The results
showed that it was promising to improve the quality control of
SFI with few markers to determine the multicomponents. In
summary, the proposed UPLC-PDA method with few markers
to determine multicomponents can be employed as a useful
tool to evaluate the quality of TCMs. Although the method
recommended here is considered to be an alternative tech-
nique when there is a shortage of chemical references, it
should not be neglected of the potential fluctuation in relative
correction factors in different laboratories for more precise
results. Interlab cross validation is needed in further research.Conflict of interest
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